Exosomics SpA has announced their implementation of NanoFCM Co., Ltd’s NanoAnalyzer to support contract research and measurement services. The partnership will enable Exosomics to become NanoFCM’s approved service provider of nano-flow cytometry measurements.
Dr Dimitri Aubert, Managing Director of NanoFCM Co., Ltd stated, "Thanks to their NanoAnalyzer, Exosomics will be able to supply the widest range of nano-flow cytometry measurements, which are in high demand across Europe and the rest of the world. We are delighted to recommend Exosomics to our close collaborators wishing to access the NanoAnalyzer platform on a punctual basis, or as part of a wider range of services that would accelerate internal research and development capabilities".
Dr Antonio Chiesi, CEO of Exosomics SpA went on to say, "This instrument will also allow us to further develop our own liquid biopsy pipeline, which requires the highest level of accuracy and reproducibility".